Cell Reports (Sep 2023)

TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation

  • Qianjin Guo,
  • Zi-Ming Cheng,
  • Hector Gonzalez-Cantú,
  • Matthew Rotondi,
  • Gabriela Huelgas-Morales,
  • Purushoth Ethiraj,
  • Zhijun Qiu,
  • Jonathan Lefkowitz,
  • Wan Song,
  • Bethany N. Landry,
  • Hector Lopez,
  • Cynthia M. Estrada-Zuniga,
  • Shivi Goyal,
  • Mohammad Aasif Khan,
  • Timothy J. Walker,
  • Exing Wang,
  • Faqian Li,
  • Yanli Ding,
  • Lois M. Mulligan,
  • Ricardo C.T. Aguiar,
  • Patricia L.M. Dahia

Journal volume & issue
Vol. 42, no. 9
p. 113070

Abstract

Read online

Summary: The TMEM127 gene encodes a transmembrane protein of poorly known function that is mutated in pheochromocytomas, neural crest-derived tumors of adrenomedullary cells. Here, we report that, at single-nucleus resolution, TMEM127-mutant tumors share precursor cells and transcription regulatory elements with pheochromocytomas carrying mutations of the tyrosine kinase receptor RET. Additionally, TMEM127-mutant pheochromocytomas, human cells, and mouse knockout models of TMEM127 accumulate RET and increase its signaling. TMEM127 contributes to RET cellular positioning, trafficking, and lysosome-mediated degradation. Mechanistically, TMEM127 binds to RET and recruits the NEDD4 E3 ubiquitin ligase for RET ubiquitination and degradation via TMEM127 C-terminal PxxY motifs. Lastly, increased cell proliferation and tumor burden after TMEM127 loss can be reversed by selective RET inhibitors in vitro and in vivo. Our results define TMEM127 as a component of the ubiquitin system and identify aberrant RET stabilization as a likely mechanism through which TMEM127 loss-of-function mutations cause pheochromocytoma.

Keywords